ADAR1 levels in rectal adenocarcinoma
Official title: The Effect of ADAR1 Expression Level on Total Neoadjuvant Treatment Response in Locally Advanced Rectal Cancer
Run by Necmettin Erbakan University · NCT07108348 · Data updated 2026-11-12
For people with locally advanced rectal adenocarcinoma getting total neoadjuvant therapy, clinicians will measure ADAR1 levels to see if they relate to how the tumor responds.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Necmettin Erbakan University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Konya, Meram) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | July 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | August 7, 2025 |
| Trial ID | NCT07108348 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histologically confirmed local or locally advanced rectal adenocarcinoma, ECOG 0–2, planned for TNT, and willing to provide informed consent and tissue samples are the ideal candidates.
✕Probably not a fit
Patients with metastatic disease, a second primary cancer, contraindications to chemo/radiation, or those who do not provide consent or tissue samples are unlikely to benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study measuring ADAR1 (adenosine deaminase acting on RNA1) expression in tumor tissue from patients with local or locally advanced rectal adenocarcinoma treated with total neoadjuvant therapy (TNT). Tumor staging and response will be documented using colonoscopy and pelvic MRI, and ADAR1 levels will be correlated with clinical and radiologic response and treatment decisions (surgery versus watch-and-wait). Eligible participants are ECOG 0–2, have no metastatic disease, and have no contraindications to chemotherapy or radiotherapy. The study is conducted at Necmettin Erbakan University with collaboration from the Turkish Society of Medical Oncology.
Why it matters
Potential benefit: If successful, ADAR1 measurement could help predict who will respond to TNT and support decisions about avoiding surgery or choosing sphincter-sparing approaches.
How similar studies have gone: ADAR1 has been linked to tumor behavior in other cancer types, but its value as a predictive biomarker for TNT response in rectal cancer has not been firmly established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological and staging diagnosis of local/locally advanced rectal cancer * ECOG performance score between 0 and 2 * No contraindications for chemotherapy (CT) and/or radiotherapy (RT) Exclusion Criteria: * Those diagnosed with metastatic rectal cancer * Those suspected of having rectal cancer or patients with a diagnosis of a second primary cancer * Those who have not signed the informed consent form * Those with contraindications for chemotherapy (CT) and/or radiation therapy (RT)
Where it's running
-
Necmettin Erbakan University Faculty of Medicine, Departmen of Medical Oncology
Konya, Meram, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Ahmet Oruç, MD
- Email: mdahmetoruc@gmail.com
- Phone: +90 0505 704 50 20
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adaptive radiation boost to try to preserve the rectum in people with rectal adenocarcinoma
This trial tries adding an MRI-guided adaptive radiation boost after standard chemoradiation for adults with localized rectal adenocarcinoma to better target tumor cells and spare healthy tissue.
-
Periodontal Infection and Inflammatory Markers in Missed Abortion
Researchers will test whether gum infection and inflammation are linked to missed abortion in pregnant women with no major chromosomal problems.
-
Salivary biomarkers in people with periodontitis and type 2 diabetes
This study tests whether saliva levels of apelin, chemerin, ghrelin, and lipocalin-2 differ across people with periodontitis, type 2 diabetes, both, or neither.
-
Effect of smartphone use on neck posture and function in RA/AS patients and healthy controls
This study tests how smartphone use relates to neck posture, tongue pressure, balance, and neck-related disability in people with rheumatoid arthritis or ankylosing spondylitis compared with healthy individuals.
-
Turkish Oral Assessment Sheet for checking mouth health in older adults.
This project will test whether the Turkish version of the Oral Assessment Sheet works well for people aged 60 and older to check lips, tongue, saliva, swallowing, and voice.
-
Home-based exercise after cervical epidural steroid injection for neck and arm pain
This project will test whether adding an eight-week home exercise program after a cervical epidural steroid injection helps adults with chronic cervical radiculopathy have less pain and better neck function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.